Drug-carrying bacterial outer membrane vesicle nanoparticles and preparation method and application thereof

The target of multidrug-resistant bacteria was solved by encapsulating H89 and colistin in lipid nanoparticles and encapsulating them on bacterial outer membrane vesicles that express antibacterial antibody fragments. To eliminate the problem, it has achieved efficient and safe antibacterial effects.

CN118634313BActive Publication Date: 2024-12-03GUANGDONG YUNZHAO MEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410660600.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-27
Publication Date
2024-12-03
Estimated Expiration
2044-05-27

Smart Images

  • Figure CN118634313B_ABST
    Figure CN118634313B_ABST
Patent Text Reader

Abstract

The present invention relates to the technical field of preparation of antibacterial drugs, and specifically to a drug-loaded bacterial outer membrane vesicle nanoparticle and a preparation method and application thereof. The preparation method comprises the following steps: mixing drug-loaded nanoliposomes and bacterial outer membrane vesicles, and preparing the drug-loaded bacterial outer membrane vesicle nanoparticles by a membrane extrusion method, wherein the surface of the bacterial outer membrane vesicles expresses ClyA-antiPAO1-flag protein, and the drugs carried by the drug-loaded liposomes are colistin and H89.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of preparation of antibacterial drugs, and in particular to drug-loaded bacterial outer membrane vesicle nanoparticles and a preparation method and application thereof. Background Art

[0002] Due to the overuse and misuse of antibiotics, MDR bacteria have emerged, especially the ESKAPE group, rendering once-effective antibiotics ineffective and posing a serious threat to public health. Once antibiotic resistance mechanisms rise, especially those of persistent bacteria, bacteria that survive antibiotic pressure will widely spread resistance mechanisms at an alarming rate. Given the severity of the current situation, a more promising and stable antimicrobial strategy combined therapy is needed to provide effective treatment against MDR pathogens.

[0003] Colistin is known as the "last line of defense" in the antibiotic world and has a killing effect on almost all Gram-negative bacilli. In medical treatment, colistin is often used as a last resort antibiotic, but it has been associated with unforeseen side effects, such as nephrotoxicity and hepatotoxicity. The antibacterial agent N-[(2-p-bromo-cinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89) is considered to be a protein kinase a inhibitor that can induce apoptosis in HeLa cancer cells. In order to reduce the side effects of colistin and H89, combining traditional antibiotics with antibacterial compounds is a promising treatment strategy. The combined use of synergistic antibiotics can significantly reduce the dose of a single drug required to kill bacteria, minimize side effects, and effectively prevent the emergence of drug resistance.

[0004] Liposomes and polymer micelles are commonly used drug carriers. However, drug delivery vesicles have limited applications due to the difficulty in controlling targeted delivery to bacterial infection areas. Improving the delivery efficiency of targeted drug delivery is essential for killing MDR bacteria. In particular, targeted drug delivery to bacteria has the advantages of improving drug penetration into bacteria, enhancing the accumulation of antimicrobial drugs in bacteria, and reducing collateral damage to normal microbiota. In addition, targeted drug delivery can also expand the therapeutic efficacy of local areas. Antibody-antibiotic conjugates (AACs) were first proposed in 2015, which provide more precise antibiotics with bactericidal ability in vivo. However, due to the time-consuming and costly antibody purification process, the research progress of AACs has been slow and is not suitable for large-scale antibacterial applications. Therefore, we proposed a new method for targeting bacteria, namely engineered OMVs (bacterial outer membrane vesicles). Unlike AACs, OMVs express antimicrobial antibody fragments to achieve specific antigen-antibody protein binding ability, enhance the stability and biocompatibility of nanomaterials, and prolong blood circulation time on the surface of nanomaterials. YaleYue et al. have demonstrated the targeting advantages of engineered OMVs in cancer by extracting OMV-PD1 to effectively target PD-L127 on the surface of tumor cells.

[0005] Engineered OMVs are particularly important in combating pathogenic bacterial infections, but no one has yet proposed engineered OMVs to target bacteria. Summary of the invention

[0006] In view of the shortcomings of the existing technology, in order to ensure the stability and efficient transport of H89 and colistin and overcome poor solubility, we used lipid nanoparticles (LNPs) as carriers to efficiently encapsulate H89 and colistin, and then wrapped the bacterial outer membrane vesicles targeting PAO1 in the outer membrane of the encapsulated body to generate a new nano drug-loaded particle with targeted killing ability against MDR bacteria such as Pseudomonas aeruginosa, opening up a new way to develop new targeted drugs to kill MDR bacteria.

[0007] The invention provides a method for preparing drug-loaded bacterial outer membrane vesicle nanoparticles, comprising the following steps: mixing drug-loaded nanoliposomes and bacterial outer membrane vesicles, and preparing the drug-loaded bacterial outer membrane vesicle nanoparticles by a membrane extrusion method, wherein the surface of the bacterial outer membrane vesicles expresses ClyA-antiPAO1-flag protein, and the drugs carried by the drug-loaded liposomes are colistin and H89.

[0008] When preparing the drug-loaded bacterial outer membrane vesicle nanoparticles of the present invention, the weight ratio of the bacterial outer membrane vesicles to the drug-loaded nanoliposomes is 1:2.

[0009] The PDI of the drug-loaded bacterial outer membrane vesicle nanoparticles of the present invention is less than 0.3 micrometers, and specifically the particle size of the bacterial outer membrane vesicles is 80-200 nm, specifically 80-120 nm, and more specifically 80-110 nm.

[0010] The bacterial outer membrane vesicles are obtained from Escherichia coli, preferably, the bacterial outer membrane vesicles are obtained by inducing expression of an Escherichia coli mutant lacking the msbB gene, and the Escherichia coli strain is MG1655. Further preferably, the condition for inducing expression is: adding 0.05% L-arabinose.

[0011] The drug-loaded nanoliposomes simultaneously load colistin and H89, and efficiently encapsulate the two drugs. The drug-loaded liposomes may be ordinary drug-loaded liposomes. Preferably, the drug-loaded nanoliposomes are prepared by the following method:

[0012] H89, DPPC, DMPG and cholesterol are mixed in chloroform, and then the chloroform is evaporated to prepare a lipid film by a rotary evaporation method. The obtained lipid film is then hydrated in a PBS solution of colistin, and then the hydrated solution is subjected to a freeze-thaw cycle to obtain the drug-loaded nanoliposome.

[0013] The ratio of the raw materials is 8:1:1 in molar ratio of DPPC, DMPG and cholesterol, and 1:100 in mass ratio of H89 and phospholipid. Phospholipid is the mass sum of DPPC, DMPG and cholesterol.

[0014] The PBS solution of colistin is a PBS buffer solution in which colistin is dissolved. Exemplarily, the PBS buffer solution may be a PBS buffer solution with a pH of 7.4, containing 0.24 g / L potassium dihydrogen phosphate, 1.44 g / L sodium dihydrogen phosphate, 8.0 g / L sodium chloride, 0.2 g / L potassium chloride, and the remainder being water. The amount of colistin and PBS buffer solution in the PBS solution of colistin is 0.1 mg colistin and 1 mL PBS buffer solution.

[0015] More preferably, the temperature of the freeze-thaw cycle is -196°C to 50°C.

[0016] Further preferably, the drug-loaded nanoliposomes are formed into double-layer vesicles by extrusion, and then mixed with the bacterial outer membrane vesicles, and the drug-loaded bacterial outer membrane vesicle nanoparticles are prepared and fused by membrane extrusion method.

[0017] In any of the above-mentioned film extrusion methods, the extrusion pressure may be 0.2-0.4 MPa, specifically 0.3 MPa.

[0018] In any of the above-mentioned film extrusion methods, the pore size of the extruded film is 100-400 nm, specifically 200-400 nm, more specifically 100 nm.

[0019] The extrusion parameters of any of the above-mentioned membrane extruders may be: extrusion pressure of 0.3 Mpa, filter membrane pore size of 100 nm, and repeated extrusion 10 times.

[0020] The present invention also provides drug-loaded bacterial outer membrane vesicle nanoparticles prepared by the preparation method.

[0021] The present invention also provides an antibacterial drug, comprising the drug-loaded bacterial outer membrane vesicle nanoparticles. The antibacterial is antibacterial. Exemplarily, the bacteria may be Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Salmonella enteritidis, Vibrio parahaemolyticus, etc.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] The present invention uses lipid nanoparticles (LNPs) as carriers to efficiently encapsulate drugs H89 and colistin to obtain drug-loaded liposomes LNP-H89-Coli, which ensures the stability and efficient transport of H89 and colistin and overcomes poor solubility. At the same time, the outer membrane vesicles targeting PAO1 are wrapped on the surface of the drug-loaded liposomes, and the obtained drug-loaded bacterial outer membrane vesicle nanoparticles LNP-H89-Coli@OMV have good targeted killing ability against MDR bacteria such as Pseudomonas aeruginosa, opening up a new way to develop new targeted drugs to kill MDR bacteria. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Schematic diagram of the synthesis and antibacterial mechanism of LNP-H89-Coli@OMV according to an embodiment of the present invention, wherein (a) is a synthetic route map; (b) is a schematic diagram of the antibacterial performance mechanism of LNP-H89-Coli@OMV targeting MDR PAO1 during skin biofilm infection.

[0025] Figure 2 Schematic diagram of the structure of plasmid pBAD_clyA-antiPAO1-flag.

[0026] Figure 3 The results of protein expression test, wherein (a) is the result of protein expression after 4 hours of induction with 0.01% l-arabinose; (b) is the result of protein blot test after 4 hours of induction with 0.01% l-arabinose; (c) is the result of protein expression after 24 hours of induction with 0.01% l-arabinose; (d) is the result of protein blot test after 24 hours of induction with 0.01% l-arabinose;

[0027] Figure 4Characteristic analysis results of LNP-H89-Coli@OMV, TEM images of LNP-Coli (a), LNP-H89 (b), LNP-H89-Coli (c) and LNP-H89-Coli@OMV (d); (e) Test results of protein expression of OMV and LNP-H89-Coli@OMV nanoparticles; (f) DLS particle size measurement results of LNP, LNP-H89, LNP-Coli, LNP-H89-Coli and LNP-H89-Coli@OMV; (g) Zeta potential of P-H89, LNP-Coli, LNP-H89-Coli, LNP-H89-Coli@OMV and OMV-antiPAO1-flag; (h) UV-visible absorption spectra of H89, Coli, LNP-H89, LNP-Coli, LNP-H89-Coli and LNP-H89-Coli@OMV; (i) Release curve of colistin in LB medium at room temperature and 220 rpm; (j) Release curve of H89 in LB medium at room temperature and 220 rpm;

[0028] Figure 5 Storage release curves of H89 at 4°C in different media conditions: (a) PBS solution and (b) LB broth medium;

[0029] Figure 6 Storage-release curves of Coli at 4°C in different media conditions: (a) PBS solution and (b) LB broth medium.

[0030] Figure 7 Storage release curves of H89 at 4°C in different media conditions: (a) PBS solution and (b) LB broth medium;

[0031] Figure 8 Storage-release curves of Coli at 4°C in different media conditions: (a) PBS solution and (b) LB broth medium.

[0032] Fig. 9The test results of the bactericidal performance of each nanoparticle, the chessboard diagram of the antibacterial activity of H89 in combination with colistin (a), kanamycin (b), ampicillin (c) and norfloxacin (d); (e) FICI values ​​when H89 was used in combination with various antibiotics; (f) survival of MDR bacteria in the exponential phase under different treatments; (g) survival of MDR bacteria under different treatments; (h) different treatments in PAO1. Growth curves of bacterial killing rate; (i) Survival of PAO1 biofilms under different treatment conditions; (g) Flow cytometry detection of bacterial uptake of LNP-H89-Coli@OMV@DiR; (k) Detection results of live / dead biofilms in the same medium after different treatments under persistent PAO1 infection conditions: (i) control, (ii) LNP-H89, (iii) LNP-Coli, (iv) LNP-H89-Coli, (v) LNP-H89-Coli@OMV, stained with Syto9 (green) and PI (red), respectively.

[0033] Fig.10 Flow cytometric analysis results of biofilm bacterial uptake (a) control and (b) LNP-H89-Coli@ep OMV@DiR.

[0034] Fig.11 Flow cytometric analysis results of biofilm bacterial uptake at different times: (a) 0h, (b) 1h, (c) 2h, (d) 3h, (e) 4h and (f) 6h.

[0035] Fig.12 Confocal microscopy results for biofilm bacteria uptake;

[0036] Fig.13 The results of the LNP-H89-Coli@OMV cytotoxicity test;

[0037] Fig.14 Figure 3. The in vivo antibacterial effect of LNP-H89-Coli@OMV. (a) Schematic diagram of the construction of the animal model and the treatment process. (b) In vivo photoacoustic imaging of mice in different treatment groups; (c) Fluorescence image analysis of mouse biofilms at different time points; (d) Bacterial count analysis of biofilms in different treatment groups; (e) ELISA analysis results of TNF-a in the serum of infected mice after different treatments; (f) ELISA analysis results of IL-6 in the serum of infected mice after different treatments; (g) Histological examination results of skin tissues of infected mice after H&E staining under different treatments.

[0038] Fig.15 These are the results of histological analysis of the mouse's major organs, including the heart, liver, spleen, lung, kidney, and brain.

[0039] Fig.16The results of biochemical index analysis in liver and kidney serum of mice.

[0040] Fig.17 Results of fluorescence image analysis of biodistribution in mouse organs and biofilms.

[0041] Fig.18 For the in vitro antibacterial test effect of H89, (a) Comparison of the percentage changes of ROS, caspases, membrane depolarization, DNA fragments and PS exposure in the MG1655 strain, H89 treatment group and control group; (b) Comparison of fluorescence image detection; (c) Expression results of RpoB and RecA proteins; (d) Percentage changes of ROS, caspases, membrane depolarization, DNA fragments and PS exposure in the ΔrecA strain, H89 treatment group and control group; (e) GO classification of differentially expressed proteins between the H89 treatment group and the control group. (f) Volcano map of differentially expressed proteins between the H89 treatment group and the control group; (g) Comparison of gene expression between the H89 treatment group and the control group; (h) Detection results of potential target genes in the E. coli knockout library under the H89 treatment group.

[0042] Fig.19 Bacterial killing rate of MG1655 under H89 treatment.

[0043] Fig. 20 Fluorescence image detection results of ROS levels in MG1655 under H89 treatment.

[0044] Fig.21 Flow cytometry results of ROS levels in MG1655 strain under different treatments, (a) control (b) H89.

[0045] Fig. 22 Flow cytometry results of caspase levels in MG1655 strain under different treatments, (a) control (b) H89.

[0046] Fig.23 Flow cytometry results of membrane depolarization in MG1655 strain under different treatments, (a) control (b) H89.

[0047] Fig.24 Flow cytometry results of phosphatidylserine exposure in MG1655 strain under different treatments, (a) control (b) H89.

[0048] Fig.25 Flow cytometry results of DNA fragmentation in MG1655 strain under different treatments, (a) control (b) H89.

[0049] Fig.26Flow cytometry results of ROS levels in △recAMG1655 strain under different treatments, (a) control (b) H89.

[0050] Fig. 27 Flow cytometry results of caspase levels in △recAMG1655 strain under different treatments, (a) control (b) H89.

[0051] Fig.28 Results of flow cytometry detection of depolarization in △recAMG1655 strain under different treatments, (a) control (b) H89.

[0052] Fig.29 Flow cytometry results of phosphatidylserine exposure in △recAMG1655 strain under different treatments, (a) control (b) H89.

[0053] Fig.30 Flow cytometry results of DNA fragmentation in △recAMG1655 strain under different treatments, (a) control (b) H89.

[0054] Fig.31 These are the staining detection results of bacterial chromosomes in the △recAMG1655 strain under different treatments.

[0055] Fig.32 The results of killing experiments of different genes. DETAILED DESCRIPTION

[0056] The following examples are provided for better understanding of the present invention, but are not intended to limit the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are purchased from conventional biochemical reagent stores unless otherwise specified.

[0057] In the following embodiments:

[0058] The culture medium used was LB broth [Miller (Luria–Bertani) (BD, 244620)].

[0059] The strains and plasmids used are listed in Table 1 .

[0060] Table 1 List of strains

[0061]

[0062]

[0063] Plasmid and strain construction methods

[0064] In this study, the plasmid was constructed using the internal fusion cloning technology (TaKaRa, 638943). pBAD was linearized with restriction endonucleases NcoI and PstI. pDS132 was linearized with restriction endonuclease XbaI. In-frame deletion mutants were constructed based on SacB-mediated allele exchange with suicide plasmid pDS132.

[0065] The mutants used Escherichia coli MG1655 as the parent strain.

[0066] The recA, clpX, and clpP deletion and pBAD_clyA-antiPAO1-flag plasmids were constructed using the primers in Table 2 .

[0067]

[0068]

[0069] In the examples, transmission electron microscopy (TEM) images were obtained using Tecnai G2 F20 S-Twin.

[0070] In the Examples, in vivo bioimaging analysis was performed using an IVIS Lumina XR system.

[0071] In the Examples, confocal laser scanning microscopy (CLSM) images were captured using a Nikon A1R confocal system.

[0072] In the embodiment, the absorption spectrum is tested using a UV-3101 spectrophotometer.

[0073] Example 1 Preparation of bacterial OMV-antiPAO1 and extracellular vesicles

[0074] 1. Bacterial OMV-antiPAO1 was prepared in the ΔmsbB (pBAD_clyA-antiPAO1-flag) strain. Specific reference: Li, Y. et al. Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition. ACS Nano 14, 16698-16711 (2020).

[0075] 2. Extract bacterial colonies from LB agar, then place into 20 mL LB broth medium and culture overnight at 37°C with shaking at 220 rpm.

[0076] 3. Add fresh LB broth medium at a ratio of 1:100, and when the optical density (OD600) is between 0.5 and 0.55 (exponential phase), add 0.05% L-arabinose (LB broth medium, 1:200 dilution) to induce the expression of ClyA-antiPAO1-flag protein. Incubate overnight at 37°C, 220 rpm shaking.

[0077] 4. After completing step 4, centrifuge at 8000 g for 10 min, pass the supernatant through a 0.45 μm polyvinylidene fluoride filter (Millipore, R8SA47939, USA), and concentrate to 2 mL using a 100 kDa ultrafiltration membrane (Millipore, R3EA06699, USA). The concentrate is filtered using a 0.22 μm filter and then stored at -20°C until use.

[0078] Example 2 Preparation of drug-loaded nanoliposomes

[0079] 2-0LNP liposomal nanoparticles

[0080] 83.7 mg DPPC (Avanti Polar Lipids Inc.), 10.8 mg DMPG (Avanti Polar Lipids Inc.) and 5.5 mg cholesterol (Avanti Polar Lipids Inc.) were mixed in 10 ml chloroform, and the chloroform was evaporated. Then, a lipid film was prepared by rotary evaporation to obtain an LNP lipid film.

[0081] The LNP lipid film was passed through a polycarbonate membrane with a pore size of 100 nm using an Avanti microextruder to form LNP liposome nanoparticles.

[0082] 2-1LNP-Coli liposome nanoparticles

[0083] 83.7 mg DPPC (Avanti Polar Lipids Inc.), 10.8 mg DMPG (Avanti Polar Lipids Inc.) and 5.5 mg cholesterol (Avanti Polar Lipids Inc.) were mixed in 10 ml chloroform, and then the chloroform was evaporated. Then, a lipid film was made by rotary evaporation. The obtained lipid film was hydrated in a colistin-PBS solution (the solution concentration was 0.1 mg colistin dissolved in 1 mL PBS buffer). The hydrated solution was then subjected to freeze-thaw cycles (-196°C-50°C) to encapsulate colistin to obtain LNP-Coli liposomes.

[0084] The colistin not encapsulated by liposomes was removed using a Float-A-Lyzer G2 dialysis apparatus at 4°C.

[0085] The LNP-Coli liposomes were extruded through a polycarbonate membrane with a pore size of 100 nm using an Avanti microextruder to form LNP-Coli liposome nanoparticles.

[0086] 2-2LNP-H89 liposome nanoparticles

[0087] 1 mg H89 (DC Chemical, DC7835), 83.7 mg DPPC (Avanti Polar Lipids Inc.), 10.8 mg DMPG (Avanti Polar Lipids Inc.) and 5.5 mg cholesterol (Avanti Polar Lipids Inc.) were mixed in 10 ml chloroform, and the chloroform was evaporated. Then, a lipid film was prepared by rotary evaporation. The obtained lipid film was hydrated in a PBS solution. The hydrated solution was then subjected to a freeze-thaw cycle (-196°C-50°C) to encapsulate H89 to obtain LNP-H89 liposomes, in which the molar ratio of DPPC, DMPG and cholesterol was 8:1:1, and the mass ratio of H89 to these phospholipids was 1:100.

[0088] H89 not encapsulated by liposomes was removed using a Float-A-Lyzer G2 dialysis apparatus at 4°C.

[0089] The LNP-H89 liposomes were extruded through a polycarbonate membrane with a pore size of 100 nm using an Avanti microextruder to form LNP-Coli liposome nanoparticles.

[0090] 2-3LNP-H89-Coli liposome nanoparticles

[0091] 1 mg H89 (DC Chemical, DC7835), 83.7 mg DPPC (Avanti Polar Lipids Inc.), 10.8 mg DMPG (Avanti Polar Lipids Inc.) and 5.5 mg cholesterol (Avanti Polar Lipids Inc.) were mixed in 10 ml chloroform, and the chloroform was then evaporated. Then, a lipid film was made by rotary evaporation. The obtained lipid film was then hydrated in a colistin-PBS solution (the solution concentration was 0.1 mg colistin dissolved in 1 mL PBS buffer), and the hydrated solution was then subjected to freeze-thaw cycles (-196°C-50°C) to encapsulate colistin and H89 to obtain LNP-H89-Coli liposomes.

[0092] Colistin and H89 not encapsulated by liposomes were removed using a Float-A-Lyzer G2 dialysis apparatus at 4°C.

[0093] The encapsulated LNP-H89-Coli liposomes were extruded through a polycarbonate membrane with a pore size of 100 nm using an Avanti microextruder to form LNP-H89-Coli liposome nanoparticles.

[0094] Example 3 Preparation of LNP-H89-Coli@OMV Nanoparticles

[0095] The encapsulated drug-loaded nanoliposomes LNP-H89-Coli obtained in Example 2-3 were passed through a polycarbonate membrane with a pore size of 100 nm using an Avanti micro extruder to form double-layer vesicles.

[0096] Then it was mixed with the OMVs-antiPAO1 outer membrane vesicles obtained in Example 1 at a mass ratio of 2:1, and repeatedly extruded through a polycarbonate membrane with a pore size of 100 nm using an Avanti micro extruder, with an extrusion pressure of 0.3 MPa and an extrusion frequency of 10 times to obtain LNP-H89-Coli@OMV nanoparticles.

[0097] During membrane extrusion, mechanical force promoted the membrane fusion of OMV and LNP-H89-Coli. The successful fusion was also confirmed by SDS-PAGE and Western blotting.

[0098] Experimental example

[0099] Analytical test methods:

[0100] Western blot test

[0101] Bacteria were collected and lysed with 4X LaemmLi lysis buffer after treatment. Equal amounts of protein (10 μL) were loaded into the wells of the SDS-PAGE gel and run until the indicator reached the bottom. The transfer sandwich was assembled and transferred to a PVDF membrane (Biorad, 1620177). After blocking with 8% milk, incubated overnight at 4°C in the primary antibody solution of the target protein. After incubation with the secondary antibody, the target protein was detected using a chemiluminometer. The flag protein was detected using an antibody (rabbit monoclonal antibody; ab205606, Abcam, USA). The total protein concentration was quantified using NanoDrop (Thermo Scientific, USA) and the bicinchinic acid protein assay.

[0102] Minimum inhibitory concentration (MIC) of H-89

[0103] Minimum inhibitory concentrations were determined as previously described1. H-89 was stored at a stock concentration of 5 mg / mL in dimethyl sulfoxide (DMSO) (Chemcruz, sc-358801). All compound solutions were stored at room temperature. Three test colonies were picked from LB agar and placed in 1 mL LB at 37°C and 220 rpm overnight. Then diluted 1:100 into 3 mL fresh LB broth (BD, 244620). Cultured until the optical density (OD600) was between 0.5 and 0.55, i.e., entered the exponential phase. The cells were diluted into LB medium at 0.05 OD600. Two-fold serial dilutions of the test compounds were prepared. The diluted bacteria were added to a 96-well plate containing serial dilutions of antibiotics. Cultured at 37°C for 24 hours. Growth (OD600) values ​​were recorded using a Tecan Infinite M200 PRO multi-function microplate reader, and MIC curves were plotted using GraphPad Prism 5 software. The experiments were performed with biological replicates.

[0104] Checkerboard test and synergistic analysis

[0105] In brief, colonies were picked from LB agar and placed in 1 mL LB at 37°C and 220 rpm overnight. Then diluted 1:100 into 3 mL fresh LB (BD, 244620). Cultured until the optical density (OD600) was between 0.5 and 0.55, that is, entered the exponential phase. The cells were diluted into LB medium at 0.05 OD600. Two-dimensional arrays of antibiotic and compound series concentrations were prepared separately. The final volume of the drug mixture was 100uL. 100 μL of diluted bacteria was added to a 96-well plate and cultured at 37°C overnight. The OD600 of the plate was measured. Growth (OD600) values ​​were recorded using a Tecan Infinite M200 PRO multi-function microplate reader, and the data were analyzed using GraphPad Prism 5 software. We also calculated the partial inhibition concentration index (FICI) to measure the interaction between H89 and different antibiotics (PMID: 19995928). All experiments were performed with biological replicates. The calculation formula of FICI is as follows, where CHE represents H89 and AB represents antibiotics.

[0106]

[0107] Killing test and killing time

[0108] Killing test, pick up colonies from LB agar, put them into 1mL LB, 37°C, 220rpm overnight. Then dilute them into fresh LB (BD, 244620) at a ratio of 1:100. Cultivate until the optical density (OD600) is between 0.5 and 0.55, that is, treat them after the exponential phase. Different treatments will be performed. In order to measure CFU / mL, collect 200μL culture solution and wash it once with high pressure 1x phosphate buffer (PBS) (Chemcruz, sc-24947). Then perform 10-fold serial dilutions with 1xPBS. 5μL of each dilution is cultured into a square culture dish containing 20mL LB agar (Luria-Bertani) (BD, 244620). Cultivate overnight at 37°C. Only the dilutions that produce about 20 colonies are counted.

[0109] Biofilm killing test

[0110] The biofilm killing test method for persistent bacteria is as follows: pick up colonies from LB agar and place them in 1 mL LB at 37°C and 220 rpm overnight. Then dilute them into fresh LB (BD, 244620) at a ratio of 1:100. Cultivate until the optical density (OD600) is between 0.5 and 0.55, that is, enter the exponential phase. Dilute the bacteria into fresh LB broth at a ratio of 1:100, put them into 12 mL Falcon tubes equipped with 6 mm PE50 tubes (0.58 mm * 0.96 mm), and culture them in a 37°C static incubator for 72 hours to form biofilms. Rinse the PE50 tubes five times with sterile 1× PBS to remove loosely attached cells. Transfer three PE50 tubes to 1 mL fresh LB and perform deferred treatment at 37°C at 220 rpm. After 24 hours of treatment, remove the tubes and place them in fresh 1 mL sterile 1× PBS, then sonicate for 5 minutes twice to release biofilm cells. The solution was diluted 10 times in series and then cultured to examine the surviving bacteria. For confocal microscopy observation, the bacteria were inoculated into 6-well plates equipped with glass coverslips. The bacteria were cultured at 37°C for 72 hours to form biofilms. The planktonic bacteria were washed away with 1× PBS. The bacteria were then stained with 5μM SYTO 9 (Invitrogen, S34854, Carlsbad, California, USA) and 30μM PI (Invitrogen, P3566, Carlsbad, California, USA) for 20 minutes. Images were taken by Carl Zeiss LSM710 confocal.

[0111] Cytotoxicity assay

[0112] 3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide (MTT) reagent was used to detect the viability of cells with different treatments. Specifically, 293T cells were seeded on 96-well plates, each well was seeded for 24 hours, and then the cells were treated with LNP-H89-Coli@OMV (50μg / mL). The cells were then rinsed with PBS. 200μL of MTT (0.5mg / mL-1in PBS) reagent was added to each well and incubated at 37°C for 4 hours. Finally, the MTT solution was carefully removed, 150μL of DMSO was added to each well, and the 96-well plate was gently shaken at room temperature for 20 minutes. The cytotoxicity of the material was recorded using a Tecan Infinite M200 PRO multi-function microplate reader.

[0113] In vivo imaging and biodistribution

[0114] Mice were imaged using in vivo imaging 24 hours after surgery and 3, 6, 12, 24, and 36 hours after the first treatment. The excitation wavelength was 710 nm and the emission wavelength was 760 nm.

[0115] Biosafety Assessment

[0116] Mice were treated with LNP-H89-Coli@OMV (20 mg / kg). After 14 days, brain, heart, liver, spleen, lung and kidney tissues were collected and fixed in 4% buffered paraformaldehyde for 24 hours, then embedded, sectioned and stained with hematoxylin and eosin (H&E) or Gram stain, and the tissues were observed under light microscopy. Blood was collected for blood biochemical analysis. After the treatment period, all mice were euthanized and brain tissues were collected for hematoxylin and eosin (H&E) and Gram staining.

[0117] Analysis of hydroxyl radical generation in vivo (ROS level)

[0118] After different treatments, add 1 μL of carboxy-H2DCFDA (10 mM in DMSO) to 1 mL of bacteria and incubate at 37°C, 220 rpm for 1 hour. Centrifuge at 8000 rpm for 3 minutes and wash the bacteria once with 1xPBS. After filtering the cells through a 40-μm filter, analyze them using a flow cytometer (BECKMAN, CytoFLEX S, excitation wavelength: 488 nm; emission wavelength: FL1 525 / 40 nm). When using a microscope, resuspend the bacteria in 10 μL of PBS. Take 1 μL and place it on a slide for analysis using a Carl Zeiss AxioObserver with APOTOME fluorescence microscope.

[0119] Caspase enrichment assay

[0120] After different treatments, 1 μL of dye FITC-VAD-FMK In Situ Marker (Promega, G7462) was added to 1 mL of bacteria and cultured at 37°C, 220 rpm for 1 hour. 1 mL of bacteria was collected and washed twice with 1 mL of 1xPBS, centrifuged at 8000 rpm for 3 minutes. After filtering through a 40-μm filter, the cells were analyzed using a flow cytometer (BECKMAN, CytoFLEX S, excitation wavelength: 488 nm; emission wavelength: FL1 525 / 40 nm).

[0121] Membrane depolarization assay

[0122] After different treatments, 1 μL of the dye DiBAC4 was added to 1 mL of bacteria, incubated at 37°C for 15 min, then washed three times with 1xPBS and centrifuged at 8000 rpm for 3 min. The cells were filtered through a 40-μm filter and analyzed using a flow cytometer (BECKMAN, CytoFLEX S, excitation wavelength: 488 nm; emission wavelength: FL1 525 / 40 nm).

[0123] Phosphatidylserine (PS) exposure analysis

[0124] Phosphatidylserine (PS) exposure assay was performed according to the instructions of FITC Annexin V Apoptosis Detection Kit I (BD, 556547). In brief, 1 mL of bacterial cells were collected after different treatments. Then rinsed twice with pre-cooled PBS. Each sample was resuspended in 100 μL 1x binding buffer, and then 5 μl FITC Annexin V and 5 μl PI were added. The cells were gently agitated and incubated at RT (25°C) in the dark for 15 minutes. 400 μL 1X binding buffer was added to each sample. After filtering through a 40 μm filter, the cells were analyzed using a flow cytometer (BECKMAN, CytoFLEX S, excitation: 488 nm; emission: FL1 525 / 40 nm).

[0125] DNA fragment analysis

[0126] DNA fragment analysis was performed according to the instructions of APO-DIRECTTM Kit (BD Biosciences, 556381, including 51-6536AK and 51-6536BK). In brief, after different treatments, 1 mL of bacterial cells were collected and the supernatant was discarded after 8000 rpm for 3 minutes. Then rinsed twice with pre-cooled PBS. Each sample was then resuspended in 1 mL of 4% paraformaldehyde (w / v, in 1x PBS, Chemcruz, sc-281692) in PBS. The cell suspension was placed on ice for 60 minutes. Centrifuged at 8000 rpm for 5 minutes and the supernatant was discarded. Then rinsed twice with pre-cooled PBS. The supernatant was discarded, leaving 100 μL PBS. Gently vortex and resuspend the cell mass in the residual PBS in the test tube. The cell concentration was adjusted to approximately 106 cells / mL in 70% (v / v) ice-cold ethanol. Store cells in 70% (v / v) ethanol at -20°C overnight. Centrifuge at 8000 rpm for 5 minutes to pellet the cells. Aspirate off the 70% (v / v) ethanol. Then wash twice with wash buffer. Prepare 50 μl of TUNEL staining solution for each sample. The staining solution composition is shown in Table 4 below.

[0127] Table 4 DNA fragment analysis staining solution composition

[0128]

[0129] Resuspend the cells in 50 μl TUNEL staining solution. Incubate the cells in the staining solution for 60 minutes at 37°C in a temperature-controlled shaking incubator (300 rpm). After incubation, add 1 mL of wash buffer to each tube, then centrifuge at 8,000 rpm for 5 minutes and discard the supernatant. Then rinse once with wash buffer. Resuspend the cells in 500 μL PBS. After filtering the cells through a 40 μm filter, analyze them using a flow cytometer (BECKMAN, CytoFLEX S, excitation: 488 nm; emission: FL1 525 / 40 nm).

[0130] DNA structure analysis

[0131] After different treatments, Hoechst 33342 and propidium iodide (PI) were added to 1 mL of bacteria, incubated at 37°C for 15 minutes, then washed three times with 1xPBS and centrifuged at 8000 rpm for 3 minutes. The cells were then resuspended with 10 μL PBS. 1 μL was taken onto a microscope slide and analyzed using a Carl Zeiss Axio Observer with APOTOME fluorescence microscope. The excitation wavelength of PI was 617 nm and the excitation wavelength of Hoechst 33342 was 455 nm.

[0132] Experimental Example 1 Sample Testing and Characterization

[0133] The basic properties of the samples were tested and characterized through transmission electron microscopy, protein expression test, DLS analysis measurement, and zeta potential test.

[0134] refer to Figure 1 In this embodiment of the present invention, LNP-H89-Coli@OMV nanoparticles were synthesized. In brief, H89 or colistin was encapsulated in a spatially stable liposome, which was produced by extrusion of 1,2-dipalmitoyl-glycero-3-3-phosphoglycerol (DMPG) and cholesterol through a 100nm membrane. Transmission electron microscopy (TEM) images showed that the sample LNP-Coli ( Figure 4 a) LNP-H89( Figure 4 b) LNP-H89-Coli( Figure 4 c) and LNP-H89-Coli@OMV( Figure 4 d) is a uniform spherical nanoparticle with an average size of about 146 nm. LNP-H89-Coli@OMV shows the typical OMV structure of Gram-negative bacteria by transmission electron microscopy.

[0135] To prepare OMVs, Escherichia coli (E. coli) was designed to express the desired protein, and then the extracted OMVs were coated on LNP-H89-E. coli to prepare LNP-H89-E. coli@OMV. More specifically, the plasmid pBAD_clyA-antiPAO1-flag ( Figure 2 ) and an in-frame deletion mutant of ΔmsbB. The sequence of plasmid pBAD_clyA-antiPAO1-flag is SED ID NO.21. The fusion protein ClyA-antiPAO1-flag contains three parts, including the variable domains of the MEDI3902 antibody scFv28 of the heavy chain and kappa chain (antiPAO1), a C-terminal tag (antiPAO1-flag) and the bacterial outer membrane protein ClyA (ClyA-antiPAO1-flag). The bispecific antibody MEDI3902 of VH and V-kappa contains the complementary determining regions CDR1, CDR2 and CDR3, which are the target PcrV component of the T3S transport system.

[0136] The knockout of the msbB gene from a juvenile pentaacylated LPS OMV is associated with reduced endotoxicity and side effects. Figure 3 a) and Western blot test results show that ( Figure 3b), successfully expressed in Δmsb (pBAD_clyA-antiPAO1-flag) under L-arabinose induction, with a predicted protein amount of 63.1 kDa. Therefore, we extracted endotoxin OMV-antiPAO1 and identified the ClyA-antiPAO1-flag on its surface ( Figure 3 c, d).

[0137] Through DLS measurement, it can be seen that the size of the particles gradually increases from LNP liposome particles to the final LNP-H89-Coli@OMV nanoparticles ( Figure 4 f) and the zeta potential gradually decreases ( Figure 4 g), which further confirmed the fusion process of LNP-H89-Coli and OMV. The diameter of the constructed LNP-H89-Coli@OMV was about 156 nm, and the zeta potential dropped to about the level of OMV.

[0138] The absorption characteristics of colistin and H89 were characterized by spectroscopy. The appearance of new absorption peaks further confirmed the loading of colistin and H89 in liposomes ( Figure 4 h).

[0139] The loading and encapsulation rate tests of H89 and colistin in LNP-Coli, LNP-H89, and LNP-H89-Coli of Example 2 are shown in Table 3.

[0140] Table 3 Drug loading and encapsulation efficiency of nanoliposomes

[0141]

[0142] To further investigate the drug leakage behavior, we performed release experiments at 37 °C and 200 rpm. The release rates of H89 and colistin in LNP-H89-Coli@OMV were as high as 60% within 12 h. Figure 4 i, j). The storage release of drugs H89 and colistin was observed by monitoring absorbance at 4°C in different media conditions: (a) PBS solution and (b) LB broth medium. Figure 5 and Figure 6 As shown, when stored at 4 °C, the leakage of H89 and colistin in LNP-H89-Coli@OMV was less than 5% after one week of storage and less than 8% after extended storage for 40 days.

[0143] DLS and zeta potential detection results ( Figure 4 f, g, Figure 7-8 ) showed that LNP-H89-Coli@OMV had good stability in water or physiological culture medium, demonstrating the potential for in vivo testing.

[0144] Experimental Example 2 Bacterial Killing Ability Experiment

[0145] 2.1 Experiment on synergistic effect of H89 and different antibiotics

[0146] Experimental method: Model Escherichia coli checkerboard test.

[0147] Experimental samples: drug H89 + colistin, drug H89 + kanamycin, drug H89 + ampicillin, and drug H89 + norfloxacin

[0148] Experimental results: To test the relationship between H89 and the normal antibiotic colistin ( Fig. 9 a) Kanamycin ( Fig. 9 b) Ampicillin ( Fig. 9 c) and norfloxacin ( Fig. 9 d) Synergistic effects in Gram-negative bacteria were tested in a checkerboard assay in the model bacterium Escherichia coli. The fractional inhibition concentration index (FICI) value was calculated as Fig. 9 As shown in Figure e, H89 has the best synergistic effect with colistin.

[0149] 2.2H89 synergistic killing experiment on MDR bacteria

[0150] Experimental method: checkerboard test. The samples acted on different MDR bacteria: Escherichia coli (p_mcr-1), Citrobacter rodentium, Salmonella Enteritidis ATCC13076, Acinetobacter baumannii ATCC 17978, Klebsiella pneumoniae ATCC BAA-2146 and Vibrio parahaemolyticus

[0151] Experimental samples: control group, LNP-Coli, LNP-H89 of Example 2, LNP-H89-Coli@OMV of Example 3 Results of LNP-H89-Coli@OMV of Example 3: Fig. 9 f, and further demonstrated that H89 had a strong synergistic effect on colistin.

[0152] 2.3 Antibacterial effect of LNP-H89-Coli@OMV on MDR bacteria

[0153] Experimental methods: Checkerboard test, planktonic culture of Escherichia coli, Escherichia coli (p_mcr-1), Acinetobacter baumannii ATCC 17978, Acinetobacter baumannii ATCC BAA-1800, Klebsiella pneumoniae ATCC BAA-2146, Citrobacter rodentium, Salmonella Enteritidis ATCC13076 and Vibrio parahaemolyticus, and treated with different experimental samples in the late exponential growth phase.

[0154] Experimental samples: control group, LNP-Coli and LNP-H89 of Example 2, and LNP-H89-Coli@OMV of Example 3.

[0155] Experimental results: It shows that the nanoparticles LNP-H89-Coli@OMV of the present invention have an effective killing effect on ESKAPE group pathogens ( Fig. 9 f), and also demonstrated significant and persistent killing effects against Escherichia coli (p_mcr-1), Acinetobacter baumannii ATCC 17978, Acinetobacter baumannii ATCCBAA-1800, and Klebsiella pneumoniae ATCC BAA-2146 ( Fig. 9 g).

[0156] At the same time, it also reflects that the killing performance of LNP-H89-Coli@OMV in the late exponential growth of PAO1 is rapid and time-dependent ( Fig. 9 h). After 8 h of treatment, the PAO1-targeted nanoparticle-coated LNP-H89-Coli@OMV showed about 100-fold antibacterial effect. In persistent bacteria, LNP-H89-Coli@OMV also showed a faster bactericidal rate ( Fig. 9 i). Flow cytometry analysis confirmed that LNP-H89-Coli@OMV can be rapidly internalized into bacteria ( Fig. 9 Confocal microscopy of persistent PAO1 pathogen uptake also showed similar results ( Fig.12). The survival of persistent pathogens was further investigated. Almost all bacteria treated with LNP-H89-Coli@OMV showed red fluorescence, indicating the effect of LNP-H89-Coli@OMV on biofilm survival.

[0157] In summary, LNP-H89-Coli@OMV exhibited good antibacterial properties against planktonic and persistent pathogens in vitro.

[0158] Experimental Example 3LNP-H89-Coli@OMV Cytotoxicity Experiment

[0159] Experimental methods: The cytotoxicity of the samples to normal cells was studied using the standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylammonium bromide (MTT) method.

[0160] Samples: LNP-H89-Coli@OMV of Example 3 and LNP-H89-Coli of Example 2.

[0161] Results: It was observed that LNP-H89-Coli@OMV showed good cellular safety ( Fig.13 ).

[0162] Experimental Example 4 In vivo therapeutic experiment of LNP-H89-Coli@OMV

[0163] Experimental model: Reference Fig.14 , mice were surgically inserted with 1 cm intravenous catheters subcutaneously. Each catheter contained 10 7 A persistent PAO1.

[0164] 24 hours after surgery, mice were randomly divided into 5 groups (n=6). Mice were repeatedly treated with tail vein injections, and the 5 groups were: (1) control (20 mg / kg), (2) LNP-H89 (20 mg / kg), (3) LNP-Coli (20 mg / kg), (4) LNP-H89-Coli (20 mg / kg), (5) LNP-H89-Coli@OMV (20 mg / kg). Treatment was once every 12 hours for 3 days. 24 hours after the last treatment, mice were euthanized, the intact catheter was removed, and 1 mL of sterile 1× PBS was used for ultrasonic treatment. After cardiac perfusion, the intact infected skin was embedded in paraffin and sectioned. The homogenate was serially diluted 10 times, and 100 μL of the sample after each dilution was spread on LB agar plates to count the number of surviving bacteria.

[0165] The animal experiment was approved by the Research Ethics Committee of the University of Macau (UMARE-033-2020).

[0166] 4.1 Comparison of in vivo targeting ability of LNP-H89-Coli and LNP-H89-Coli@OMV:

[0167] The in vivo targeting ability of LNP-H89-Coli@OMV nanoparticles was compared with that of uncoated LNP-H89-Coli nanoparticles. The treatment results showed that the accumulation of biofilm PAO1 in the venous catheter was significantly higher and longer in LNP-H89-Coli@OMV compared with the uncoated OMV group ( Fig.14 b, Fig.17 ).

[0168] 4.2 Evaluation of the therapeutic effect of LNP-H89-Coli@OMV in vivo

[0169] In this study, the in vivo therapeutic effect of LNP-H89-Coli@OMV was evaluated by using a BALB / c intravenous biofilm catheter to display a persistent PAO1 infection model. Mice were randomly divided into five groups after biofilm placement surgery: (1) control group (20 mg / kg), (2) LNP-H89 (20 mg / kg), (3) LNP-Coli (20 mg / kg), (4) LNP-H89-Escherichia coli (20 mg / kg), and (5) LNP-H89-Coli@OMV (20 mg / kg). Treatment was started one day after the bacterial infection surgery. Laser speckle imaging was used to monitor the changes in subcutaneous blood vessels during the progression of infection.

[0170] Monitoring results such as Fig.14 As shown in c, we found that the subcutaneous blood flow in the back was significantly reduced 1 day after bacterial infection. In the LNP-H89-Coli@OMV treatment group, microvessels gradually regenerated, subcutaneous blood flow gradually increased, and the volume of cortical lesions was significantly reduced.

[0171] It is well known that PAO1 biofilms in intravenous catheters are particularly difficult to eradicate and are associated with limited treatment and high mortality, especially in immunocompromised patients. These changes indicate that the LNP-H89-Coli@OMV nanoparticles of the present invention are very effective in promoting recovery from infectious diseases.

[0172] The results showed that the LNP-H89-Coli@OMV treatment group significantly reduced the bacterial load compared with the control group, resulting in an approximately 1,000-fold reduction in bacteria in the mouse brain tissue ( Fig.14 d). Enzyme-linked immunosorbent assay (ELISA) of immune factors is used to understand the inflammatory response in the body and assess the severity of inflammation caused by bacteria. Fig.14As shown in e and f, the proinflammatory cytokines TNF-α and interleukin-6 (IL-6) in the LNP-H89-Coli@OMV group were significantly reduced compared with the control group, indicating that the degree of skin inflammation caused by persistent PAO1 infection was significantly reduced in the LNP-H89-Coli@OMV treatment. We then performed H&E staining on the infected lesion skin tissue caused by persistent PAO1. The results of histological analysis showed that in the first four treatments, there were obvious necrotic areas (circles), capillary congestion (squares), and mixed inflammatory infiltration composed of mononuclear / multinuclear cells (triangles) ( Fig.14 g). Significant reduction and increase in necrotic areas in subcutaneous adipocytes (arrows) and intact epidermis (diamonds) indicated that LNP-H89-Coli@OMV nanoparticles could effectively recover from persistent PAO1 infection.

[0173] 4.3 Biosafety Assessment:

[0174] The biosafety of LNP-H89-Coli@OMV was evaluated before in vivo therapeutic experiments.

[0175] Mice were treated with LNP-H89-Coli@OMV (20 mg / kg). After 14 days, brain, heart, liver, spleen, lung and kidney tissues were collected and fixed in 4% buffered paraformaldehyde for 24 hours, then embedded, sectioned and stained with hematoxylin and eosin (H&E) or Gram stain, and the tissues were observed under light microscopy. Blood was collected for blood biochemical analysis. After the treatment period, all mice were euthanized and brain tissues were collected for hematoxylin and eosin (H&E) and Gram staining.

[0176] We observed that LNP-H89-Coli@OMV showed good cell safety, such as heart, liver, spleen, lung, and kidney, indicating that tissue morphology was normal after LNP-H89-Coli@OMV treatment ( Fig.15 ), indicating that LNP-H89-Coli@OMV did not cause any significant tissue damage. In addition, blood biochemical analysis showed little change compared with the control group 14 days after intravenous injection ( Fig.16 ).

[0177] In summary, the above results indicate that LNP-H89-Coli@OMV has good killing stability and superior biosafety, and is a promising candidate for nanodrugs.

[0178] Study on the sterilization mechanism of experimental example 5H89

[0179] The antibacterial mechanism of the nanoparticle LNP-H89-Coli@OMV of the embodiment of the present invention can be divided into two parts: colistin and H89. As the last line of defense against MDR bacteria, the mechanism of action of colistin has been systematically and thoroughly studied. It interacts with lipopolysaccharide and phospholipid A on the bacterial cell membrane, destroys the potential and integrity of the cell membrane, interferes with the normal function of the bacterial membrane, causes leakage of cell contents and intake of exogenous substances, reduces bacterial resistance to other antibiotics, and enhances the bactericidal effect at non-lethal colistin concentrations. Based on this, we speculate that the bactericidal mechanism of colistin and H89 is that sublethal concentrations of colistin mediate the destruction of bacterial membranes, thereby promoting the accumulation and bactericidal ability of H89.

[0180] H89 was first discovered as an antibacterial compound, and its bactericidal mechanism is still unclear. In order to further study the mechanism of action of H89 in the bacterial killing process, the changes in the bacterial killing rate of MG1655 under H89 treatment were first studied. Fig.19 Then, the apoptotic-like death (ALD) characteristics were detected under the appropriate killing time point treatment. Fig. 20 ) and flow cytometry ( Fig.18 a, Fig.21 ), a significant positive level of green DCF fluorescence was observed, which strongly suggested that H89 induced the generation of ROS. To further detect characteristic markers of apoptosis, such as increased caspase, membrane deacylation, and phosphatidylserine exposure, we used FITC-conjugated peptide pan-caspase inhibitor Z-VD-FM, fluorescently labeled DIBAC4, and fluorescently labeled Annexin V dye, respectively. Flow cytometry showed a significant fluorescence intensity, strongly suggesting that there was increased caspase, membrane depolarization, and phosphatidylserine exposure in the initial stage of H89-induced apoptosis ( Fig.18 a, Figure 22-24 ).

[0181] Then, terminal deoxynucleotidyl transferase dUTP end labeling (TUNEL) detection was used to study DNA fragmentation. In LNP-CHE-Coli treatment, only FITC-coupled dUTP signal was detected, indicating that its killing process was accompanied by DNA fragmentation ( Fig.18 a, Fig.25 ). The structure of bacterial chromosomes was monitored by confocal microscopy using the nuclear-specific dyes Hoechst 33342 and PI. In the presence of H89, Hoechst and PI showed higher fluorescence intensity, indicating that its killing process was accompanied by chromosome condensation ( Fig.18b) Daniel J Dwyer et al. found that RecA is an important caspase-like protein in ALD33. In recA mutants, the ALD characteristics caused by the antibiotic norfloxacin were significantly reduced, and ClpX and ClpP were also confirmed to be important ALD-related proteins.

[0182] Table 5 MIC values ​​of H89 of different gene strains

[0183] strains MIC (μg / mL) MG1655 6.215 MG1655△recA 6.828 MG1655△clpX 5.056 MG1655△clpP 7.273

[0184] Therefore, we wanted to verify whether H89-induced caspase-dependent ALD is also related to RecA. ΔrecA, ΔclpX, and ΔclpP E. coli were obtained by suicide plasmid and homology arm exchange, and the gene knockout results were successfully verified by PCR. Western blot showed that the expression of RecA protein was significantly reduced ( Fig.18 c). We detected H89 MIC in ΔrecA, ΔclpX and ΔclpP strains, which showed no significant difference compared with the wild type (Table 5). The preliminary conclusion is that ALD induced by H89 is not related to recA, clpX and clpP. Fig.18 As shown in d, flow cytometry detected significant positive signals for ALD. Specifically, the ROS level ( Fig.26 ), increased caspase ( Fig. 27 ), membrane depolarization ( Fig.28 ), phosphatidylserine exposure ( Fig.29 )、DNA fragment( Fig.30 ) and chromosome condensation ( Fig.31 ). Taken together, these findings deepen our understanding of the antibacterial mechanism of H89, which can induce ALD independently of RecA, ClpX, or C, and the potential caspase-like ALD proteins induced by H89 need to be further discovered.

[0185] To further uncover the bactericidal mechanism of H89, we performed proteomic analysis of HG1655 under H89 treatment. Quantifiable proteins were identified in three biological replicates. Fig.18 e shows the proteomic and bioinformatic analysis of H89 treatment. These data were analyzed by graphene oxide enrichment analysis in biological processes, cellular components and molecular functions. In the volcano plot ( Fig.18 f) and histogram ( Fig.18g) shows the differential expression of proteins. Red dots indicate upregulated proteins and green dots indicate downregulated proteins. Gray dots indicate proteins with no change in abundance between the two groups. Proteins with corrected P values ​​< 0.05 and abundance fold change > 2 or < 0.5 were classified as differentially expressed between the two groups. We then analyzed genes that showed significant changes in the proteomic analysis. The screening experiments were performed at 2 times the MIC concentration of H89 in the KEIO library.

[0186] like Fig.18 h, the screening results showed several possible h89-related genes. Further, we analyzed the killing assay of three strains of miaA::Kan, pyrE::Kan and cpxP::Kan and found that the killing ability of miaA::Kan was significantly reversed ( Fig.32 ). Since the E. coli strain in the KEIO library is BW25113, we also performed MIC detection on the experimental strain MG1655 by constructing a fusion miaA mutant. The results showed that the MIC of H89 in the miaA mutant was significantly increased compared with the wild-type MG1655 (Table 5). In summary, the killing mechanism of H89 is related to miaA, and more detailed mechanisms require further discovery.

[0187] In summary, it can be seen that in order to ensure the stability and efficient transport of H89 and colistin and overcome poor solubility, the present invention uses lipid nanoparticles (LNPs) as carriers to efficiently encapsulate drugs to obtain nanoliposome particles (LNP-H89-Coli). In addition, a msbB mutant Escherichia coli (strain MG1655) was designed, which fused the ClyA coding region with the bacterial scFv to produce outer membrane vesicles (OMV) that selectively target PAO1, and then the OMV-antiPAO1 obtained by genetic engineering was wrapped on the surface of LNP-H89-Coli by membrane extrusion to form a new drug-loaded bacterial outer membrane vesicle nanoparticle LNP-H89-Coli@OMV ( Figure 1 a), the nanoparticles have targeted killing capabilities against MDR bacteria such as Pseudomonas aeruginosa. Its antibacterial mechanism is mainly divided into two parts. Colistin disrupts the bacterial cell membrane and promotes the effective entry of H89. H89 induces apoptotic-like cell death by fully activating apoptotic features, including DNA fragmentation, chromosome condensation, caspase activation, membrane depolarization, phosphatidylserine exposure, and cell filamentation. Further proteomic analysis showed that H89 may target the MiaA protein. In addition to in vitro experiments, in vivo experiments were also conducted to demonstrate that the nanoparticles have the potential to treat biofilm infections ( Figure 1 b), the nanoparticles can be used in antibacterial drugs, which can open up new avenues for the development of new targeted drugs to kill MDR bacteria.

[0188] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0189] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A method for preparing drug-loaded bacterial outer membrane vesicle nanoparticles, characterized in that: The method comprises the following steps: mixing drug-loaded nanoliposomes and bacterial outer membrane vesicles, and preparing the drug-loaded bacterial outer membrane vesicle nanoparticles by a membrane extrusion method; the surface of the bacterial outer membrane vesicles expresses ClyA-antiPAO1-flag protein, and the drugs loaded in the drug-loaded liposomes are colistin and H89. The bacterial outer membrane vesicles are derived from Escherichia coli, which is Escherichia coli MG1655 containing plasmid pBAD_clyA-antiPAO1-flag and an in-frame deletion mutant of ΔmsbB constructed using gene editing technology, and the Escherichia coli MG1655 is induced to express ClyA-antiPAO1-flag protein by adding 0.05% L-arabinose. The sequence of the plasmid pBAD_clyA-antiPAO1-flag is shown in SED ID NO.

21.

2. The preparation method according to claim 1, characterized in that: The weight ratio of bacterial outer membrane vesicles to drug-loaded nanoliposomes was 1:

2.

3. The preparation method according to claim 1, characterized in that: The drug-loaded nanoliposomes are prepared by the following method: H89, DPPC, DMPG and cholesterol are mixed in chloroform, and then the chloroform is evaporated to prepare a lipid film by a rotary evaporation method. The obtained lipid film is then hydrated in a PBS solution of colistin, and then the hydrated solution is subjected to a freeze-thaw cycle to obtain the drug-loaded nanoliposome.

4. The preparation method according to claim 3, characterized in that: The molar ratio of DPPC, DMPG and cholesterol is 8:1:1, and the mass ratio of H89 to phospholipid is 1:

100.

5. The preparation method according to claim 4, characterized in that: The temperature of the freeze-thaw cycle is -196℃~50℃.

6. The preparation method according to any one of claims 1 to 5, characterized in that: The drug-loaded nanoliposomes are formed into double-layer vesicles by extrusion, and then mixed with the bacterial outer membrane vesicles to prepare the drug-loaded bacterial outer membrane vesicle nanoparticles by membrane extrusion.

7. The preparation method according to claim 6, characterized in that: The film extrusion method uses an extruded film of 100-400 nm.

8. Drug-loaded bacterial outer membrane vesicle nanoparticles prepared by the preparation method according to any one of claims 1 to 7.

9. An antibacterial drug comprising the drug-loaded bacterial outer membrane vesicle nanoparticles as claimed in claim 8.